低风险甲状腺微小乳头状癌主动监测结局与左甲状腺素治疗状态的关系
2005至2019年共2509例低风险甲状腺微小乳头状癌患者接受主动监测,按是否接受左甲状腺素(LT4)治疗分组。诊断时已用LT4组10年疾病进展率2.9%,未用LT4组6.1%(p=0.091);监测期间起始LT4组10年进展率13.8%,显著高于未用LT4组5.0%和诊断时已用LT4组2.9%(p<0.01)。结论认为LT4治疗可能与主动监测期间肿瘤生长减缓有关,但需进一步确证研究。
要点
- 监测期间起始LT4组10年疾病进展率13.8%,高于未用LT4组的5.0%和诊断时已用LT4组的2.9%(p<0.01)。
- 监测期间起始LT4组用药前肿瘤体积倍增率0.095/年,高于未用LT4组的-0.0085/年和诊断时已用LT4组的-0.057/年(p<0.01)。
- 多因素分析中监测期间起始LT4与疾病进展独立相关(OR=3.42,95%CI 2.15-5.44,p<0.01)。
核心结论
- LT4治疗可能与甲状腺微小乳头状癌主动监测期间肿瘤生长减缓有关,但需进一步确证研究。
研究设计与样本
- 2005至2019年共2896例低风险甲状腺微小乳头状癌患者接受主动监测,其中2509例纳入分析:诊断时未用LT4者2187例(I组),监测期间未用LT4者1935例(IA组),监测期间起始LT4者252例(IB组),诊断前或诊断时已用LT4者322例(II组)。
- 计算基于超声的肿瘤体积倍增率和肿瘤大小,以及时间加权详细TSH评分;疾病进展定义为肿瘤增大≥3 mm和(或)出现新发淋巴结转移。
主要发现
- 诊断时II组较I组有更多高危特征(如更年轻、肿瘤更大),但II组10年疾病进展率2.9%低于I组6.1%(p=0.091)。
- IB组10年疾病进展率13.8%显著高于IA组5.0%和II组2.9%(p<0.01)。
- IB组LT4给药前肿瘤体积倍增率0.095/年显著高于IA组-0.0085/年和II组-0.057/年(p<0.01),提示主动监测期间出现进展征象的患者被选择性处方LT4。
- IB组LT4给药后时间加权详细TSH评分较给药前显著下降(3.35 vs 3.05,p<0.01);肿瘤体积倍增率从0.13/年降至0.036/年(p=0.08);快速或中度生长患者比例从26.8%降至12.5%(p<0.01)。
- 多因素分析显示IB组状态与疾病进展独立相关(OR=3.42,95%CI 2.15-5.44,p<0.01),年龄≥40岁且<60岁(OR=0.23,95%CI 0.14-0.38,p<0.01)和年龄≥60岁(OR=0.16,95%CI 0.10-0.27,p<0.01)与疾病进展独立负相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出LT4治疗与主动监测期间肿瘤生长减缓的关联需进一步确证研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: During active surveillance (AS), serum thyrotropin (TSH) levels may affect papillary thyroid microcarcinoma (PTMC) progression. We investigated AS outcomes according to whether levothyroxine (LT4) treatment was administered. Patients and Methods: From 2005 to 2019, 2896 patients with low-risk PTMC underwent AS. Of these, 2509 patients were included: 2187 patients did not receive LT4 at diagnosis (group I), 1935 patients did not receive LT4 during AS (group IA), and 252 patients started LT4 during AS (group IB). The remaining 322 patients were administered LT4 before or at diagnosis (group II). The tumor volume doubling rate (TVDR) and tumor size based on ultrasound examination results and time-weighted detailed TSH scores were calculated. Disease progression was defined as tumor enlargement ≥3 mm and/or the appearance of novel lymph node metastasis. Results: At diagnosis, group II had more high-risk features, such as younger age and larger tumors, than group I. However, group II had a lower disease progression rate (2.9% at 10 years) than group I (6.1%) (p = 0.091). The disease progression rate of group IB (13.8% at 10 years) was significantly higher than that of groups IA (5.0%) and II (2.9%) (p < 0.01). The TVDR of group IB before LT4 administration was significantly higher than that of groups IA and II (0.095 per year, -0.0085 per year, and -0.057 per year, respectively; p < 0.01), suggesting that patients with progression signs during AS were selectively prescribed LT4. The time-weighted detailed TSH score of group IB significantly decreased after LT4 administration compared with those before administration (3.35 and 3.05, respectively; p < 0.01). The TVDR also decreased from 0.13 per year to 0.036 per year (p = 0.08). The proportions of patients with rapid or moderate growth decreased significantly after LT4 (from 26.8% to 12.5%, p < 0.01). A multivariable analysis revealed group IB status was independently associated with disease progression (odds ratio [OR] = 3.42 [CI 2.15-5.44], p < 0.01), whereas age ≥40 years and <60 years and age ≥60 years were independently negatively associated with this outcome (OR = 0.23 [CI 0.14-0.38, p < 0.01 and OR = 0.16 [CI 0.10-0.27], p < 0.01). Conclusion: LT4 treatment may be associated with decreased tumor growth during AS of PTMC, but further confirmatory research is needed.
引用
- Yamamoto M, Miyauchi A, Ito Y, et al. Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status. Thyroid. 2023. PMID: 37310904. doi:10.1089/thy.2023.0046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。